Sie befinden sich hier
Inhalt
MI3-Kick-Off-Symposium
MI3-Kick-Off-Symposium
29th September 2022, 01.30 – 06:00 p.m.
MI3-Retreat
30th September 2022, 09:00 a.m. – 05:00 p.m.
Medical Faculty Mannheim, Heidelberg University
Alte Brauerei, Lecture Room 2
Röntgenstrasse 7, 68167 Mannheim
We are pleased to announce that we have put together an exciting program for both our MI3-Retreat as well as for our MI3-Kick-Off Symposium featuring top international/national leaders in the field of innate immunity.
New Option of Treatment for Second-line Therapy of Advanced Oesophageal Cancer
A UMM initiated “RAMONA study” presents worldwide for the first time a combined immune therapy option with two Checkpoint inhibitors as a safe and effective treatment for older patients. Patients with advanced and refractory oesophageal squamous cell carcinoma who do not respond to the first-line radiation therapy and/or chemo therapy face poor prognosis and there has been no standard second-line therapy
The “RAMONA study” led by Professor Dr. Matthias Ebert, head of the Department of Medicine II of the University Medical Center Mannheim (UMM) and Professor of Internal Medicine at Heidelberg University was conducted in over 30 centers in Germany. This trial provides new evidence for a new treatment option with immune therapy in these older patients.
New regulator of gene expression discovered
Biochemists at MI3 and the National Cancer Institute (USA) identified the E3-ligase RNF219 as a novel inhibitor of mRNA deadenylation.
New funding to investigate the dark side of chemotherapy
DFG funds Middle East Cooperation grant to investigate the immunology behind the metastasis-promoting effects of chemotherapy.
Insights into the childhood of an mRNA
A newly developed method to investigate early stages in the life of mRNA offers new insights into a poorly characterized mechanism of gene regulation.
How „paralyzed“ immune cells can be reactivated against brain tumors
Brain tumor cells carrying a specific and frequent mutation were found to reprogram infiltrating immune cells and thereby paralyze the body’s own defense against the tumor. Scientists from Heidelberg, Mannheim and Freiburg discovered a mechanism to reactivate the paralyzed immune system and promote its anti-cancer function.
New Research Training Group in the Field of Immunology
DFG funds Graduate School/GRK2727 "Innate Immune Checkpoints in Cancer and Tissue damage" with 5.3 million euros
Neues Baden-Württembergisches Netzwerk zur Verringerung von Tierversuchen
Mit dem Ziel, die Zahl von Tierversuchen zu reduzieren und den Tierschutz weiter zu verbessern, entsteht in Baden-Württemberg ein neues Netzwerk: Es bündelt neue Ansätze und Maßnahmen an den biomedizinischen Forschungsstandorten des Landes, die nach dem international anerkannten 3R-Prinzip Replacement (Vermeidung), Reduction (Verringerung), Refinement (Verbesserung) die Belastungen für die Versuchstiere begrenzen und die Versuchstierzahl immer weiter senken sollen.
DGfI Stellungnahme zur Impfung gegen SARS-CoV-2 vom 01.03.2021
Zur Impfung gehen – bitte jetzt! Alle zugelassenen Impfstoffe sind sicher und schützen effektiv vor einer schweren COVID-19-Erkrankung. Um die wichtigen Impfziele möglichst schnell zu erreichen, und angesichts der steigenden Frequenz der mutierten SARS-CoV-2 Varianten ist dringend zu raten, alle verfügbaren Impftermine wahrzunehmen, unabhängig vom vorgesehenen Impfstoff!
Cancer cells are masters of disguise
Article by Prof. Dr. Adelheid Cerwenka - Ruperto Carola Forschungsmagazin „Freund & Feind“ – Ausgabe 17, Februar 2021
Myeloid-Derived Suppressor Cells in Action
Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression. Groth C, Arpinati L, Shaul ME, Winkler N, Diester K, Gengenbacher N, Weber R, Arkhypov I, Lasser S, Petrova V, Augustin HG, Altevogt P, Utikal J, Fridlender ZG, Umansky V. Cancers (Basel). 2021 Feb 10;13(4):726. doi: 10.3390/cancers13040726. PMID: 33578808.
Das angeborene Immunsystem scharfschalten und damit die Resistenz gegenüber Krebsimmuntherapien überwinden?
Projekt der Medizinischen Fakultät Mannheim und des DKFZ hat beim Merck Heidelberg Innovation Call überzeugt
Die meisten Formen des Darmkrebses (Kolorektales Karzinom, CRC) sind gegenüber den derzeit überwiegend erforschten Krebsimmuntherapien, die auf die erworbene Immunabwehr setzen, resistent. Kann man die Therapieresistenzen überwinden, indem man zusätzlich die angeborene Immunabwehr ankurbelt?
NK Cells in Cancer Therapy
Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity. Ni J, Wang X, Stojanovic A, Zhang Q, Wincher M, Bühler L, Arnold A, Correia MP, Winkler M, Koch PS, Sexl V, Höfer T, Cerwenka A. Immunity. 2020;52:1075.
Kick-Off Retreat
MI3 holds its opening retreat on March 5, 2020. The core and asscoiate members will convene to talk about the first interdisciplinary projects and the next milestones of the new research institute at the Medical Faculty Mannheim of Heidelberg University.